Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.

Autor: Pelaia C; Respiratory Medicine Unit, University 'Magna Græcia' of Catanzaro - Catanzaro, Italy., Busceti MT; Respiratory Medicine Unit, University 'Magna Græcia' of Catanzaro - Catanzaro, Italy., Crimi C; Department of Clinical and Experimental Medicine, University of Catania - Catania, Italy., Carpagnano GE; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari - Bari, Italy., Lombardo N; Department of Medical and Surgical Sciences, University 'Magna Græcia' of Catanzaro - Catanzaro, Italy., Terracciano R; Department of Experimental and Clinical Medicine, University 'Magna Græcia' of Catanzaro - Catanzaro, Italy., Vatrella A; Department of Medicine, Surgery, and Dentistry, University of Salerno - Salerno, Italy., Pelaia G; Department of Health Sciences, University 'Magna Græcia' of Catanzaro - Catanzaro, Italy. Electronic address: pelaia@unicz.it.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Sep; Vol. 129, pp. 110444. Date of Electronic Publication: 2020 Jun 24.
DOI: 10.1016/j.biopha.2020.110444
Abstrakt: Background: The humanized monoclonal antibody benralizumab targets the α subunit of the interleukin-5 (IL-5) receptor and the FcγRIIIa receptor expressed by natural killer cells. Through this dual mechanism of action, benralizumab neutralizes the pro-eosinophil functions of IL-5 and promotes eosinophil apoptosis.
Objectives and Methods: The present real-life study aimed to evaluate, in 22 allergic patients with severe eosinophilic asthma, the effects of benralizumab on asthma exacerbations and lung hyperinflation.
Results: In this regard here we show that, after 24 weeks of add-on treatment, benralizumab completely depleted peripheral blood eosinophils (from 810 to 0 cells/μL; p < 0.0001), and significantly decreased both asthma exacerbation number (from 4 to 0; p < 0.0001) and residual volume (from 2720 to 2300 mL; p < 0.01). Moreover, at the same time point (24 weeks) benralizumab also increased pre-bronchodilator FEV 1 (from 1295 to 1985 mL; p < 0.0001), FVC (from 2390 to 2974 mL; p < 0.0001), FEF 25-75 (from 0.6 to 1.42 L/sec; p < 0.0001), IC (from 1940 to 2460 mL; not significant), and ACT score (from 14.73 to 22.95; p < 0.0001), as well as reduced prednisone intake (from 25 to 0 mg; p < 0.0001).
Conclusion: In conclusion, our results suggest that via its anti-eosinophil actions benralizumab improved airflow limitation, lung hyperinflation, and respiratory symptoms, as well as lowered asthma exacerbation rate and abrogated OCS consumption in most patients.
(Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: